Application of recombinant human leukemia inhibitory factor (LIF) produced in rice (Oryza sativa L.) for maintenance of mouse embryonic stem cells.

Embryonic and induced pluripotent stem cells have the ability to differentiate into any somatic cell type, and thus have potential to treat a number of diseases that are currently incurable. Application of these cells for clinical or industrial uses would require an increase in production to yield adequate numbers of viable cells. However, the relatively high costs of cytokines and growth factors required for maintenance of stem cells in the undifferentiated state have the potential to limit translational research. Leukemia inhibitory factor (LIF), a member of the IL-6 cytokine family, is a key regulator in the maintenance of naïve states for both human and mouse stem cells. In this study, we describe a new recombinant human LIF (rhLIF) using a plant-based (rice) expression system. We found that rice-derived rhLIF possessed the same specific activity as commercial Escherichia coli-derived LIF and was capable of supporting mouse embryonic stem cell proliferation in the undifferentiated state as evidenced from pluripotency marker level analysis. Retention of the pluripotent state was found to be indistinguishable between rice-derived rhLIF and other recombinant LIF proteins currently on the market.

[1]  S. Pettit,et al.  Expression, purification, and characterization of recombinant human transferrin from rice (Oryza sativa L.). , 2010, Protein expression and purification.

[2]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[3]  R. Rodriguez,et al.  The tissue-specific activity of a rice beta-glucanase promoter (Gns9) is used to select rice transformants , 2001 .

[4]  Donald Metcalf,et al.  Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells , 1988, Nature.

[5]  T. Springer,et al.  Expression and induction in vitro of macrophage differentiation antigens on murine cell lines. , 1983, Journal of immunology.

[6]  Xiaopan Chen,et al.  Establishment of an exogenous LIF-free culture system for mouse embryonic stem cells. , 2009, Cloning and stem cells.

[7]  Gordon Keller,et al.  Differentiation of Embryonic Stem Cells to Clinically Relevant Populations: Lessons from Embryonic Development , 2008, Cell.

[8]  Ian Chambers,et al.  The transcriptional foundation of pluripotency , 2009, Development.

[9]  H. Holzhausen,et al.  Characterization of a pluripotent stem cell line derived from a mouse embryo. , 1984, Experimental cell research.

[10]  P. Mee,et al.  Embryonic stem cells: understanding their history, cell biology and signalling. , 2005, Advanced drug delivery reviews.

[11]  T. Matsui,et al.  Expression and regulation of the leukemia inhibitory factor/D factor gene in human T-cell leukemia virus type 1 infected T-cell lines. , 1992, Cancer research.

[12]  D. Solter,et al.  Monoclonal antibody defining a stage-specific mouse embryonic antigen (SSEA-1). , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Austin G Smith,et al.  Signalling, cell cycle and pluripotency in embryonic stem cells. , 2002, Trends in cell biology.

[14]  H. Hirai,et al.  Establishment of LIF-Dependent Human iPS Cells Closely Related to Basic FGF-Dependent Authentic iPS Cells , 2012, PloS one.

[15]  S. Pettit,et al.  Characterization of transferrin receptor-mediated endocytosis and cellular iron delivery of recombinant human serum transferrin from rice (Oryza sativa L.) , 2012, BMC Biotechnology.

[16]  J. Gimble,et al.  Toward a clinical-grade expansion of mesenchymal stem cells from human sources: a microcarrier-based culture system under xeno-free conditions. , 2011, Tissue engineering. Part C, Methods.